Hydroxychloroquine market

Hydroxychloroquine Market , By Disease Indication (Malaria, Coronavirus Disease, Lupus Erythematosus, and Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Request Free Sample

Jul 2023
CMI3727
145 Pages
Excel & Pdf
Pharmaceutical

Summary

The Global Hydroxychloroquine Market is estimated to be valued at US$ 599.8 Mn in 2023 and is expected to exhibit a CAGR of 5.7% during the forecast period (2023-2030).

Analysts’ Views on Global Hydroxychloroquine Market :

Increasing number of novel drug approvals are expected to boost the growth of the global hydroxychloroquine market over the forecast period. For instance, in April 2020, European Medical Agency- the main drug regulatory authority of Europe, clarified the use of chloroquine and hydroxychloroquine for COVID-19. Hydroxychloroquine was used for national emergency use programmes in COVID-19 patients whose condition was critical.

Figure 1. Global Hydroxychloroquine Market Share (%), by Disease Indication, 2023

Source: Coherent Market Insights Analysis (2023)

Global Hydroxychloroquine Market – Driver

Increasing prevalence of diseases like Psoriatic Arthritis

The growing prevalence of diseases like Psoriatic Arthritis across the world is expected to aid in growth of the global hydroxychloroquine market. For instance, according to an article published in Plos One- a open access journal, Spain had the highest cases of Psoriatic Arthritis in Europe, followed by Norway. The use of hydroxychloroquine, as a drug treatment for Psoriatic Arthritis can drive the growth of the global hydroxychloroquine market.

Increasing collaboartions and license agreements

The increasing partnerships among pharmaceutical can drive the growth of the global hydroxychloroquine market. For instance, in July 2021, Sanofi- a France based multinational pharmaceutical and healthcare company and Asahi Kasei Corporation- a Japan based multinational chemical company, executed a marketing license agreement to transfer sales right in Japan for hydroxychloroquinine tablets. Sanofi remained as the marketing authorization holder of hydroxychloroquine Japan and continued manufacturing the product.

Figure 2. Global Hydroxychloroquine Market Share (%), by Region, 2023

Source: Coherent Market Insights Analysis (2023)

Global Hydroxychloroquine Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global hydroxychloroquine market over the forecast period. This is due to the increasing number of research and development activities on diseases like Lupus Erythematosis in the U.S. For instance, according to an article published on May 4, 2023, by Labiotech-a digital media platform focused at Biotech industry in Europe, the research by Vanderbilt University Medical Center- medical provider with multiple hospitals in the U.S, uncovered that patients with lupus have higher levels of iron in their T cells. This condition is called Hemochromatosis and can lead to general fatigue and joint pain. The use of hydrochloroquine to treat lupus can help balance iron levels among patients.

Global Hydroxychloroquine Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global hydroxychloroquine market. This is because, in the early stages of the pandemic, hydroxychloroquine was suggested as a possible prevention method or treatment for COVID-19. Countries manufacturing hydroxychloroquine were also encouraged to import it to different countries. For instance, in April 2020, India approved supply of hydroxychloroquine to 55 countries as commercial sales or grants.

Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 599.8 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	5.7%	2030 Value Projection:	US$ 882.8 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Disease Indication: Malaria, Coronavirus Disease, Lupus Erythematosus, Rheumatoid Arthritis By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Sanofi, Amneal Pharmaceuticals, LLC, Laurus Labs, Zydus Group, Prasco, LLC, Dr. Reddy's Laboratories, Ltd, Cadila Pharmaceuticals, Novartis AG, Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma), Covis Pharma GmbH, Cardinal Health, Aphena Pharma Solutions, Mylan N.V (A subsidiary of Vitris), McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin, Sun Pharmaceutical Industries Ltd.
Growth Drivers:	Increasing prevalence of diseases like Psoriatic ArthritisIncreasing prevalence of diseases like Psoriatic Arthritis Growing collaborations and licensing agreements among pharmaceutical companies
Restraints & Challenges:	Incompatibility with other anti viral drugs Toxic effects at high dosages

Global Hydroxychloroquine Market Segmentation:

The global hydroxychloroquine market report is segmented into disease indication, distribution channel, and country.

By Disease Indication, the market is segmented into Malaria, Coronavirus Disease, Lupus Erythematosus, Rheumatoid Arthritis. Out of which, the malaria segment is expected to hold a dominant position in the global hydroxychloroquine market during the forecast period and this is attributed to high transmission rate of the disease.

By Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Out of which, the hospital segment is expected to hold a dominant position in the global hydroxychloroquine market during the forecast period and this is attributed to increased hospitalizations.

By Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, Africa out of which, the North America segment is expected to dominate the market over the forecast period and this is attributed to the region's established healthcare infrastructure and significant product manufacturing.

Among all the segmentations, the disease indication segment has the highest potential due to the rising prevalence of the disease through rapid transmission. According to the data provided on March 23, 2023, by the World Health Organization- the United Nations agency that connects nations, partners and people to promote health, 247 million cases of malaria were detected globally in 2021 and the estimated number of deaths stood at 619,000.

Global Hydroxychloroquine Market Cross Sectional Analysis:

Among disease indication segment, Rheumatoid Arthritis segment is estimated to dominate in North America over forecast period owing to the rowing prevalence of the disease. According to an article published in June 2020, by Medical News Today- web-based outlet for medical information and news, targeted at both the general public and physicians, 1.3 million people over the age of 65 are infected with Rheumatoid Arthritis every year.

Global Hydroxychloroquine Market : Key Developments

On May 2, 2023, Icannex Healthcare- medicinal cannabinoid and psychedelic therapy development company, started its Phase II trial of cannabidiol (CBD) and hydroxychloroquine combinational therapy in Rheumatoid Arthritis.

In November, 2020, Jubilant Pharma Limited- a manufacturer and supplier of radiopharmaceuticals and Aavis Pharmaceuticals Inc- a U.S based pharmaceutical company, announced the launch of Hydroxychloroquine tablets to counter Malaria , Rheumatoid Arthritis and Lupus in the U.S.

In April 2022, the Indian government lifted a ban on the export of hydroxychloroquine, paving the way for the anti-malaria drug to be shipped to the U.S. for use against the coronavirus.

In April 2020, Galenika- Serbia based pharmaceutical company and Zada Pharmaceuticals- a Bosnia based pharmaceutical company announced the launch of a production unit of chloroquine and hydroxychloroquine for the treatment of COVID-19 patients.

Global Hydroxychloroquine Market: Key Trends

The demand for hydroxychloroquine saw an increase in the COVID 19 period due to rapid transmission of the coronavirus and the overwhelming of healthcare sytems all over the world.In May 2020, National Institute Of Health- a agency of the U.S Department Of Health And Human Services announced the beginning of clinical trials of hydroxychloroquine and azithromycin to treat COVID-19.

The COVID-19 pandemic caused the extreme shortage of drug treatments and hospitalizations rising continuously due to the load of cases of coronavirus. To counter this, In May 2020, Novartis commited to donate up to 130 million doses of hydroxychloroquine to poor subtropical countries to support the global COVID-19 pandemic response.

Global Hydroxychloroquine Market: Restraint

Toxic effects of Hydroxychloroquine at higher dosages

According to a report published by European Medical Agency- the drug regulatory body of the European Union, in April 2020, Chloroquine and hydroxychloroquine are known to induce cardiac rhythm abnormalities at higher strengths of the dose. This will slow the market's growth rate. Consumption of drugs at the right dosage strength, as recommended by the physician is an effective counterbalance to this restraint.

Incompatibility with other anti viral drugs

In June 2020, the Food and Drug Agency- the main regulatory agency of the U.S, released a statement warning clinicians that the antiviral activity of remdesivir, an investigational treatment for COVID-19 may potentially be reduced if it is coadministered with chloroquine or hydroxychloroquine.This clinical contraindication may discourage researches to combine hydroxychloroquine with other anti viral drugs, causing a fall in the uptake of the drug.

Global Hydroxychloroquine Market - Key Players

Major players operating in the global hydroxychloroquine market include Sanofi, Amneal Pharmaceuticals, LLC, Laurus Labs, Zydus Group, Prasco, LLC, Dr. Reddy's Laboratories, Ltd, Cadila Pharmaceuticals, Novartis AG, Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma), Covis Pharma GmbH, Cardinal Health, Aphena Pharma Solutions, Mylan N.V (A subsidiary of Vitirs), McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin, Sun Pharmaceutical Industries Ltd.

Global Hydroxychloroquine Market – Definition

Hydroxychloroquine is in a class of drugs called antimalarials and is also an antirheumatic drug. It works by killing the organisms that cause malaria. Hydroxychloroquine may work to treat rheumatoid arthritis and systemic lupus erythematosus by decreasing the activity of the immune system.

Table of Content

Table of Contents

*Browse 25 market data tables and 26 figures on “Hydroxychloroquine Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the Global Hydroxychloroquine Market during the forecast period (2023-2030)?

The market is estimated to be valued at US$ 599.8 Mn in 2023 and is expected to exhibit a CAGR of 5.7% between 2023 and 2030.

What are the major factors driving the market growth?

The increasing prevalence of diseases like Psoriatic Arthritis and growing partnerships and license agreements between pharmaceutical companies worldwide is expected to drive the market growth.

Which is the leading disease indication segment in the market?

Malaria is the leading disease indication segment in the market.

What are the key factors hampering the growth of the market?

Toxic effects at higher dosages and incompatibility with other anti viral drugs is expected to hinder the market over the forecast period.

Which are the major players operating in the market?

Major players operating in the market Sanofi, Amneal Pharmaceuticals, LLC, Laurus Labs, Zydus Group, Prasco, LLC, Dr. Reddy's Laboratories, Ltd, Cadila Pharmaceuticals, Novartis AG, Concordia Pharmaceuticals Inc. (A subsidiary of Advanz Pharma), Covis Pharma GmbH, Cardinal Health, Aphena Pharma Solutions, Mylan N.V (A subsidiary of Vitris), McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin, Sun Pharmaceutical Industries Ltd.